Research programme: beta-lactamase stimulants - Synthetic Biologics

Drug Profile

Research programme: beta-lactamase stimulants - Synthetic Biologics

Alternative Names: P1B; P1C; P2A; P2B; P2C; P4A; SYN-006 - Synthetic Biologics

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsat Therapies
  • Developer Synthetic Biologics
  • Class Enzymes
  • Mechanism of Action Beta lactamase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • Research Diarrhoea

Most Recent Events

  • 22 Mar 2017 Early research in Diarrhoea in USA (PO), before March 2017 (Synthetic Biologics Form10-K, March 2017)
  • 22 Mar 2017 Preclinical trials in Clostridium infections (Prevention) in USA (PO) (Synthetic Biologics Form10-K, March 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Clostridium-infections(Prevention) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top